Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX) has been making waves these past few months as investors and institutions gain confidence from the highly positive clinical trials, and the recent exclusive meeting with the FDA with regards to their NDA.
Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The lead product candidate is Silenor (doxepin) for the treatment of insomnia.
The FDA decision date on Silenor has been set to 12/4/09 for their NDA resubmission. The importance of this is discussed further in the article.
No comments:
Post a Comment